Targeting specific calcium channels in the brain's immune cells could unlock new therapeutic pathways for neurodegenerative diseases and neurological disorders. This approach addresses a critical gap in treating conditions where brain inflammation drives progressive damage. The TRPM2 channel serves as a calcium gateway in microglia, the brain's resident immune cells that become overactive in neurological diseases. When these channels are blocked, microglial inflammatory responses diminish significantly, potentially slowing disease progression. Research demonstrates that TRPM2 inhibition reduces harmful inflammatory cascades while preserving beneficial microglial functions like debris clearance. The channel's role extends beyond simple calcium regulation—it acts as a molecular switch determining whether microglia adopt protective or destructive phenotypes. This represents a fundamental shift from broad anti-inflammatory approaches toward precision targeting of specific cellular mechanisms driving neuroinflammation. The therapeutic implications span multiple neurological conditions where microglial dysfunction contributes to pathology, including Alzheimer's disease, Parkinson's disease, and stroke. However, the field faces significant challenges in translating these mechanistic insights into clinical therapies. Current TRPM2 inhibitors lack the specificity and pharmacological properties needed for human use. Additionally, the dual role of microglia—both protective and harmful depending on context—requires careful consideration of timing and dosing strategies. While promising in preclinical models, this approach remains largely theoretical for human application. The complexity of microglial biology suggests that successful therapeutics will likely require combination approaches rather than single-target strategies, making this an important but preliminary step in neurotherapeutic development.